Reaching Viral Suppression Among People With HIV With Suspected Treatment Failure who Received Enhanced Adherence Counseling in Southern Nigeria: A Retrospective Analysis.
intensive adherence counseling
people with HIV
persistent viremia
unsuppressed viral load
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
14
10
2022
entrez:
2
1
2023
pubmed:
3
1
2023
medline:
3
1
2023
Statut:
epublish
Résumé
This study assessed viral load (VL) testing and viral suppression following enhanced adherence counseling (EAC) among people with HIV (PWH) with suspected treatment failure and identified factors associated with persistent viremia. We conducted a retrospective review of electronic medical records of PWH aged 15 years or older who had received antiretroviral therapy (ART) for at least 6 months as of December 2020 and had a high viral load (HVL; ≥1000 copies/mL) across 22 comprehensive HIV treatment facilities in Akwa Ibom State, Nigeria. Patients with HVL were expected to receive 3 EAC sessions delivered in person or virtually and repeat VL testing upon completion of EAC and after documented good adherence. At 6 months post-EAC enrollment, we reviewed the data to determine client uptake of 1 or more EAC sessions, completion of 3 EAC sessions, a repeat viral load (VL) test conducted post-EAC, and persistent viremia with a VL of ≥1000 copies/mL. Selected sociodemographic and clinical variables were analyzed to identify factors associated with persistent viremia using SPSS, version 26. Of the 3257 unsuppressed PWH, EAC uptake was 94.8% (n = 3088), EAC completion was 81.5% (2517/3088), post-EAC VL testing uptake was 75.9% (2344/3088), and viral resuppression was 73.8% (2280/3088). In multivariable analysis, those on ART for <12 months ( An HVL resuppression rate of 74% was achieved, but EAC completion was low. Identification of the challenges faced by PWH with a higher risk of persistent viremia is recommended to optimize the potential benefit of EAC.
Sections du résumé
Background
UNASSIGNED
This study assessed viral load (VL) testing and viral suppression following enhanced adherence counseling (EAC) among people with HIV (PWH) with suspected treatment failure and identified factors associated with persistent viremia.
Methods
UNASSIGNED
We conducted a retrospective review of electronic medical records of PWH aged 15 years or older who had received antiretroviral therapy (ART) for at least 6 months as of December 2020 and had a high viral load (HVL; ≥1000 copies/mL) across 22 comprehensive HIV treatment facilities in Akwa Ibom State, Nigeria. Patients with HVL were expected to receive 3 EAC sessions delivered in person or virtually and repeat VL testing upon completion of EAC and after documented good adherence. At 6 months post-EAC enrollment, we reviewed the data to determine client uptake of 1 or more EAC sessions, completion of 3 EAC sessions, a repeat viral load (VL) test conducted post-EAC, and persistent viremia with a VL of ≥1000 copies/mL. Selected sociodemographic and clinical variables were analyzed to identify factors associated with persistent viremia using SPSS, version 26.
Results
UNASSIGNED
Of the 3257 unsuppressed PWH, EAC uptake was 94.8% (n = 3088), EAC completion was 81.5% (2517/3088), post-EAC VL testing uptake was 75.9% (2344/3088), and viral resuppression was 73.8% (2280/3088). In multivariable analysis, those on ART for <12 months (
Conclusions
UNASSIGNED
An HVL resuppression rate of 74% was achieved, but EAC completion was low. Identification of the challenges faced by PWH with a higher risk of persistent viremia is recommended to optimize the potential benefit of EAC.
Identifiants
pubmed: 36589481
doi: 10.1093/ofid/ofac651
pii: ofac651
pmc: PMC9792083
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofac651Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Open Forum Infect Dis. 2014 Aug 12;1(2):ofu058
pubmed: 25734128
J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):45-51
pubmed: 24872139
PLoS One. 2020 May 5;15(5):e0232576
pubmed: 32369504
BMC Public Health. 2018 Aug 22;18(1):1048
pubmed: 30134880
Lancet Infect Dis. 2018 Mar;18(3):346-355
pubmed: 29198909
J Int AIDS Soc. 2019 Nov;22(11):e25415
pubmed: 31746541
South Afr J HIV Med. 2016 Sep 30;17(1):476
pubmed: 29568618
AIDS Care. 2016 Nov;28(11):1386-93
pubmed: 27145451
AIDS Res Treat. 2020 Apr 21;2020:8909232
pubmed: 32373359
AIDS Res Treat. 2017;2017:7356362
pubmed: 29250442
AIDS. 2009 Sep 10;23(14):1867-74
pubmed: 19531928
AIDS Res Treat. 2013;2013:580974
pubmed: 23401755
PLoS One. 2019 Feb 5;14(2):e0211326
pubmed: 30721229
AIDS. 2009 Jun 1;23(9):1127-34
pubmed: 19417582
AIDS Res Ther. 2022 Jul 9;19(1):34
pubmed: 35810317
Clin Infect Dis. 2009 Jul 15;49(2):306-9
pubmed: 19522657
BMC Public Health. 2021 Dec 18;21(1):2294
pubmed: 34922502
J Telemed Telecare. 2021 Dec 30;:1357633X211070726
pubmed: 34967240
J Int AIDS Soc. 2018 Oct;21(10):e25194
pubmed: 30350392
J Acquir Immune Defic Syndr. 2015 Oct 1;70(2):e44-51
pubmed: 26375466
PLoS One. 2013;8(3):e57907
pubmed: 23472118
J Int AIDS Soc. 2021 Oct;24 Suppl 6:e25820
pubmed: 34713591